Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177-DOTATATE in Inoperable Pheochromocytoma/Paraganglioma
NCT03206060Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium Lu 177 dotatate in pheochromocytoma and Paraganglioma (PGL), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 6 months. Started Oct 2017; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03206060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206060.